Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
STRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI
STRATUS-PCI is a pilot clinical trial that compares two ways of running a small heart pump called Impella CP during a high-risk procedure to open blocked heart arteries (percutaneous coronary intervention, or PCI) in patients…
- Trial name
- STRATUS-PCI (NCT07588399)
- Testing
- Impella CP
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Rayyan Hemetsberger
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Heart Failure with Reduced Ejection Fraction HFrEF
Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF)
This study will recruit 100 patients from a post-discharge medicine clinic to test if the addition of a pharmacist to manage heart failure medications can increase appropriate use of these medications.
- Trial name
- NCT06450522
- Testing
- Pharmacist co-management of HF medication optimization, Usual care
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of British Columbia
Heart Failure With Reduced Ejection Fraction, Renal Insufficiency
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
Heart Failure (HF) poses a major health burden in various populations, with devastating annual rates of morbidity and mortality. It is estimated that 1%-to-2% of the general population suffer from the heart failure syndrome.
- Trial name
- TRIUMF (NCT04736329)
- Testing
- Telmisartan
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Cairo University
Chronic Heart Failure, Oxygen Deficiency
Oxygen Therapy in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to assess patients with chronic heart failure and moderate-severe ventricular dysfunction (left ventricular ejection fraction (FEVE) <40%) with nocturnal desaturation (mean Oxygen saturation (SatO2)…
- Trial name
- ROXIC (NCT05913739)
- Testing
- Oxygen Therapy
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-1-REF (NCT06215911)
- Testing
- Tovinontrine (CRD-750)
- Where
- 139 sites in United States, Australia and 17 more
- Volunteers
- 557 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure With Reduced Ejection Fraction
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable…
- Trial name
- Empire HF (NCT03198585)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 190 people
- Sponsor
- Morten Schou
Heart Failure, Beta-blocker
N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure
In this study we seek to understand whether N-of-1 trials using a crossover withdrawal/reversal design with 1-5 three-week periods can be used to identify the highest tolerated beta-blocker dose for patients with Heart Failure…
- Conditions
- Heart Failure, Beta-blocker, Older Adults
- Trial name
- NCT07489352
- Testing
- N-of-1 trials, Enhanced usual care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Brigham and Women's Hospital
Acute Heart Failure With Reduced Left Ventricular Ejection Fraction
Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study
Problem: Aggressive titration of guideline-directed medical therapy is the cornerstone of heart failure management to reduce heart failure related hospitalization and mortality.
- Trial name
- TOM-HF (NCT07016815)
- Testing
- Wearable wrist heart rate and activity monitor, Bluetooth enabled body weight scale with bioimpedance analysis, Bluetooth enabled electronic blood pressure device
- Where
- 2 sites in Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Heart Failure With Reduced Ejection Fraction, Heart Failure, Systolic
PhotobiomoduLation for pAtientS With Advanced hEart failuRe
The objective of the study is to examine the effectiveness of photobiomodulation therapy in patients with advanced-stage heart failure with reduced ejection fraction (HFrEF), who have been referred but ineligible for a heart…
- Trial name
- LASER (NCT06501313)
- Testing
- Photobiomodulation
- Volunteers
- 70 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Heart Failure With Reduced Ejection Fraction
Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study
The purpose of the Screening for Advanced heart failure IN stable ouTpatientS (SAINTS) study is to determine the prevalence of advanced heart failure (HF) in symptomatic patients with HF and reduced left ventricular ejection…
- Trial name
- SAINTS-A (NCT05299879)
- Testing
- Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization
- Where
- 6 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Failure With Preserved Ejection Fraction, Microvascular Angina
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
This is an observational study of Neuregulin-1 (NRG-1) plasma levels in patients with different forms of cardiovascular disease including microvascular angina (MVA), heart failure with preserved ejection fraction (HFpEF), as well…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Microvascular Angina, Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
- Trial name
- NRG-1-CVDs (NCT04391491)
- Testing
- Neuregulin-1β level in plasma
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Heart Failure
Polypill Strategy for Heart Failure With Reduced Ejection Fraction
Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of…
- Trial name
- POLY-HF (NCT04633005)
- Testing
- Polypill, Control Rx
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Reduced Ejection Fraction
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv…
- Trial name
- METEORIC-HF (NCT03759392)
- Testing
- Omecamtiv Mecarbil
- Where
- 81 sites in United States, Canada and 7 more
- Volunteers
- 276 people
- Sponsor
- Cytokinetics
Heart Failure
Comparison of Three-dimensional and Two-dimensional Left Ventricle Strain With Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
This study will compare two ultrasound techniques, 2D and 3D speckle-tracking echocardiography, for measuring how well the heart muscle contracts in patients with heart failure and reduced pumping function.
- Trial name
- 3V2-STEM-HF (NCT07741305)
- Where
- 5 sites in Italy
- Volunteers
- 419 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Sudden Cardiac Death, Sudden Cardiac Arrest
Heart Failure Optimization Study
This study is designed as a multi-center prospective observational study of newly diagnosed Heart Failure (HF) patients to test the hypothesis that additional Ejection Fraction (EF) recovery occurs between 90 and 180 days as…
- Conditions
- Sudden Cardiac Death, Sudden Cardiac Arrest, Heart Failure, Heart Failure Low Output
- Trial name
- HF-Opt (NCT03016754)
- Testing
- Wearable Cardioverter Defibrillator
- Where
- 67 sites in United States, Austria and 2 more
- Volunteers
- 602 people
- Sponsor
- Zoll Medical Corporation
Right Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction
Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests the Superiority of Right Ventricular Bifocal Stimulation Over VVI Implantable Defibrillator in Right Bundle Branch Block and Heart Failure.
RATIONALE: Cardiac resynchronization therapy (CRT) is known to improve cardiac performance and to reduce morbidity and mortality in reduced-ejection fraction heart failure (HFrEF) despite optimal medical therapy (OMT).
- Conditions
- Right Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction, Bifocal Stimulation
- Trial name
- BiPARK-HF (NCT03524001)
- Testing
- Compare VVi mode versus DDD bifocal stimulation through crossover randomization
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals